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Abstract
Background: High rates of mortality and morbidity have been described in sub-Saharan African
patients within the first few months of starting highly active antiretroviral therapy (HAART). There
is limited data on the causes of early morbidity on HAART and the associated resource utilization.
Methods: A cross-sectional study was conducted of medical admissions at a secondary-level
hospital in Cape Town, South Africa. Patients on HAART were identified from a register and HIV-
infected patients not on HAART were matched by gender, month of admission, and age group to
correspond with the first admission of each case. Primary reasons for admission were determined
by chart review. Direct health care costs were determined from the provider's perspective.
Results: There were 53 in the HAART group with 70 admissions and 53 in the no-HAART group
with 60 admissions. The median duration of HAART was 1 month (interquartile range 1-3 months).
Median baseline CD4 count in the HAART group was 57 × 106 cells/L (IQR 15-115). The primary
reasons for admission in the HAART group were more likely to be due to adverse drug reactions
and less likely to be due to AIDS events than the no-HAART group (34% versus 7%; p < 0.001 and
39% versus 63%; p = 0.005 respectively). Immune reconstitution inflammatory syndrome was the
primary reason for admission in 10% of the HAART group. Lengths of hospital stay per admission
and inpatient survival were not significantly different between the two groups. Five of the 15 deaths
in the HAART group were due to IRIS or adverse drug reactions. Median costs per admission of
diagnostic and therapeutic services (laboratory investigations, radiology, intravenous fluids and
blood, and non-ART medications) were higher in the HAART group compared with the no-
HAART group (US$190 versus US$111; p = 0.001), but the more expensive non-curative costs
(overhead, capital, and clinical staff) were not significantly different (US$1199 versus US$1128; p =
0.525).
Conclusions: Causes of early morbidity are different and more complex in HIV-infected patients
on HAART. This results in greater resource utilization of diagnostic and therapeutic services.
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Background
Highly active antiretroviral therapy (HAART) has dramat-
ically improved the prognosis of HIV infection in high-
income countries by decreasing mortality, AIDS illnesses,
and hospitalization [1-3]. In low-income countries
patients start HAART with lower baseline CD4 counts
than in high-income countries [4]. Severely immune sup-
pressed patients remain at increased risk of several com-
plications within the first few months of starting HAART.
First, although HAART reduces the incidence of AIDS-
defining events, the incidence rates remain high in the
first few months [5]. Second, immune reconstitution
inflammatory syndrome (IRIS) reactions occur more
commonly with lower baseline CD4 counts [6]. Third,
many adverse drug reactions to antiretroviral agents occur
more commonly with advanced disease [7]. Therefore it is
not surprising that there are high rates of early morbidity
[8-10] and mortality [4,8] in patients starting HAART in
low-income countries.
Few studies have assessed the causes of early morbidity on
HAART in sub-Saharan African ART programmes. Most
studies report only HIV-related morbidity [8,9] or on spe-
cific diseases like tuberculosis [11]. The cohorts in the two
West African studies [8,9] had considerably higher base-
line CD4 counts (71% >200 × 106 cells/L and median 290
× 106 cells/L) than is typical for sub-Saharan African pro-
grammes. A South African study included patients more
typical of the region, but did not include IRIS as a diagnos-
tic category [10]. IRIS was also not reported in the West
African studies [8,9].
We conducted a cross-sectional study to determine
whether the reasons for hospitalization (including all
causes), outcomes, and resource utilization during hospi-
tal admissions were different in HIV-infected patients on
HAART compared with HIV-infected patients not on
HAART in South Africa, a country with a very high HIV
prevalence.
Methods
Study Site Description
The study was conducted at G.F. Jooste Hospital, a sec-
ondary-level hospital providing care for indigent patients
referred from primary health-care providers and clinics in
the poor urban communities of metropolitan Cape Town.
A cross-sectional study was conducted to assess the spec-
trum of disease and resource utilization of medical admis-
sions to G.F. Jooste Hospital among HIV-infected patients
on HAART (HAART group) compared with those not on
HAART (no-HAART group) during a nine-month period
from July 2003 through March 2004. The patients on
HAART accessed antiretroviral therapy predominantly
from donor-funded programs in G.F. Jooste Hospital's
catchment area, because the national public sector HAART
roll-out program only commenced in 2004. The donor-
funded programs included Médecins sans Frontières
(MSF) at Khayelitsha [12]; Hannan Crusaid at Gugulethu
[13] (both operated at public sector primary care clinics);
and the joint Nelson Mandela Foundation-South African
Medical Association's Tshepang project, GF Jooste Hospi-
tal clinic. These programs followed the 2002 WHO guide-
lines for HAART in resource-limited settings, initiating
HAART at CD4+ counts < 200 × 106 cells/L or with clinical
AIDS [14].
Patients in the HAART group were identified from a regis-
try of HIV-infected patients on HAART who were admitted
to the medical wards. The registry was maintained by two
resident infectious disease physicians. Patients in the no-
HAART group were matched by gender, month of admis-
sion, and age group (18-29; 30-49; and >49 years) to cor-
respond with the first admission of each patient in the
HAART group. Subsequent admissions of patients in both
groups during the study period were also captured.
The study was approved by the University of Cape Town's
Research Ethics Committee.
Data capture and analysis
The following data were extracted by retrospective chart
review: demographic information, WHO clinical stage
prior to admission, tuberculosis treatment or prophylaxis,
cotrimoxazole prophylaxis, HAART regimen and date of
commencement, treatment administered in hospital
(medication, fluids, or blood products), investigations
during hospitalization (cross-checked with the labora-
tory's electronic database), CD4+ cell count within six
months of admission (if this was unavailable, the total
lymphocyte count was recorded), length of stay, discharge
diagnoses, discharge disposition (home/step-down facil-
ity/tertiary hospital), and survival. The data were recorded
in a spreadsheet (Excel, version 97) and checked for illog-
ical or missing entries by the database analyst. Data were
analyzed with EpiInfo, version 6. Barlett's test was used for
homogeneity of variance, which was shown to differ
between the two groups, therefore the Kruskal-Wallis test
was used to analyse differences between the outcomes and
costs of the two groups.
The study physician classified the primary reason for
admission (identified from the discharge diagnoses and a
chart review) into the following diagnostic categories:
AIDS-defining events, adverse drug reactions, HIV-related
conditions, and other medical conditions not necessarily
related to HIV. In the WHO clinical staging classification,
pulmonary tuberculosis is defined as stage 3, whilst
extrapulmonary tuberculosis is stage 4 (AIDS). Because it
was not always clear from discharge diagnoses which formBMC Infectious Diseases 2009, 9:205 http://www.biomedcentral.com/1471-2334/9/205
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of tuberculosis patients had, we did not separate tubercu-
losis by site and included all forms of tuberculosis as AIDS
illnesses. HIV-related conditions were recorded primarily
according to WHO clinical stages 1 to 4 [15]. IRIS was
defined as paradoxical deterioration of an opportunistic
disease that was diagnosed prior to HAART commence-
ment.
Costing
Costing took the perspective of the health-care provider.
The median cost per inpatient day was calculated sepa-
rately for non-curative care costs and for patient-specific
diagnostic and therapeutic costs. Patient-specific labora-
tory and therapeutic costs were calculated using a stand-
ard ingredients approach, which involves linking the
usage of resources to the cost of each resource [16]. As the
study did not use timesheets to calculate the time spent by
clinical staff with each patient, costs for these clinical staff
were included in non-curative care costs.
Non-curative care costs, including recurrent overhead and
hotel costs, capital costs, and clinical staff costs, were cal-
culated by the study economist using a standard step-
down approach [17]. Hotel costs include rent on build-
ings, utilities, ward staff (laundry, kitchen, building main-
tenance), administration, and other nonspecific services
and stores that cannot be directly linked to patient utiliza-
tion. Hotel costs at G.F. Jooste medical wards and its step-
down ward, Carnation, were assumed to be the same.
Capital costs include assets that are not used up in one
year, such as buildings, furniture, and medical equipment.
The replacement costs of buildings and equipment were
based on data from the National Health Facilities Audit
undertaken by the National Department of Health (Rod
Bennet, personal communication). These data were annu-
alized using an estimated working life of 30 years for
buildings and 5 years for equipment at a rate of 8 percent.
This real interest rate is the return on long-term govern-
ment bonds in South Africa and is similar to the rate of 10
percent in a comparable secondary facility in East Africa
[18].
Clinical staff costs included salaries of doctors (attending
physicians, medical registrars, and interns) and nurses
(chief nurses, registered nurses, nurses-in-training, and
nurse assistants). The clinical staff cost per inpatient day
was calculated by establishing the full cost of employment
(including benefits) of doctors and nurses together with
the number of full time equivalent staff working in the
medicine wards. Multiplying these two allowed us to esti-
mate the annual cost of these clinical inputs. The clinical
staff cost per inpatient day was then calculated by the for-
mula:
Annual clinical staff cost/(number of beds × average bed
occupancy × 365 days per year).
Patient-specific diagnostic and therapeutic costs included
laboratory investigations, radiology, intravenous fluids
and blood, and non-ART medications. Laboratory costs
were provided by the National Health Laboratory Service.
Drug costs were obtained from the hospital pharmacy
price list, which is derived from the 2003 Provincial Ten-
der Price List. Radiology and special investigations were
costed from the central government's Uniform Fee Sched-
ule (UPFS) 2002, inflated to the 2003 level using the con-
sumer price index, less mortgage bonds [19,20].
All costs were converted from South African Rands to U.S.
dollars at the average bank rate at the midpoint of the
study (November 2003): U.S. $1 = 6.73231 Rand [21].
The total cost for each admission was calculated by the
length of stay multiplied by non-curative costs per day,
plus total diagnostic and therapeutic costs.
Results
Between July 2003 and March 2004, 72 admissions of
HIV-infected individuals on HAART met the inclusion cri-
teria, but 2 patients' folders were lost, leaving 70 admis-
sions analyzed (53 patients, 17 with 2 admissions). Two-
hundred thirty-seven HIV-infected individuals not on
HAART who had been admitted to G.F. Jooste during the
study period were identified, and 204 patient folders from
those admissions were found. Fifty three patients in the
no-HAART group were matched with the first admission
of the 53 patients in the HAART group representing 60
admissions (6 were admitted twice, and one was admitted
thrice). Five patients in the no-HAART group were
matched by season of admission as no exact month match
could be made.
Ninety-seven percent of patients admitted on HAART
were on a non-nucleoside reverse transcriptase inhibitor
(NNRTI) regimen with dual NRTI. One patient was on
self-funded dual NRTI antiretroviral therapy, but was
included in the study in the HAART group. The median
duration of antiretroviral therapy was 1 month (inter-
quartile range 1-3 months; range 1-7 months).
The demographic and clinical characteristics of the
patients are summarized in Table 1. Prior AIDS was more
common in the HAART group admissions (p = 0.034).
There was no significant difference in median CD4 counts
between the HAART and the no-HAART groups, but only
11 no-HAART admissions had CD4 counts performed.
Total lymphocyte count (TLC) was available for 10 addi-
tional no-HAART admissions and was ≤1250 × 106 cells/L
in 4 admissions (which corresponds to a CD4 count of <
200 × 106 cells/L [22]). Availability of viral loads was very
limited at the time of the study, owing to the test's high
cost. As viral loads were only available in 15 (21%)
HAART admissions and none of the no-HAART group,
this parameter was not analyzed.BMC Infectious Diseases 2009, 9:205 http://www.biomedcentral.com/1471-2334/9/205
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Table 2 lists the primary reasons for hospital admission
among patients in the HAART and no-HAART groups.
AIDS-defining events constituted the main reason for
admission in both groups, but was significantly more
common in the no-HAART group. Conversely, drug reac-
tions were significantly more common in the HAART
group, in whom it was the second-most frequent reason
for admission. Drug reactions occurred as diagnoses other
than the primary reason for admission in a further 33 and
2 admissions in the HAART and no-HAART groups respec-
tively. Antiretrovirals accounted for 35/57 (61%) of all of
the drug reactions in the HAART group, whilst 6/6
(100%) of all the drug reactions in the no-HAART group
were from antitubercular drugs. IRIS, included in the
AIDS category, was the primary reason for admission in
seven (10%) of the HAART admissions and all occurred
within one month of the start of ART. IRIS cases were par-
adoxical deterioration of cryptococcal meningitis (n = 3)
and tuberculosis (n = 4). The median number of diag-
noses per admission was 6 (IQR 5-7) and 5 (IQR 4-7) in
the HAART and no-HAART groups respectively (p = 0.18).
Tuberculosis or its sequelae were listed as diagnoses in
110/130 (85%) admissions, (61 in the HAART group and
49 in the no-HAART group; p = 0.388). The proportion of
patients on antitubercular therapy commenced prior to
admission was 34% in the HAART group and 20% in the
no-HAART group, with a trend toward significance (p =
0.07).
Table 3 includes outcomes and length of stay. Overall,
there was no significant difference in length of stay or
death observed between the two groups. During the
admission period, there were 14 total referrals to the area's
tertiary hospital, either for special investigations (n = 9) or
admission (n = 5). The majority of the 19 deaths during
the first admission were among individuals admitted with
an AIDS-defining event (n = 10), of whom 6 were HAART
admissions and 4 were no-HAART admissions. Three per-
sons on HAART who were admitted with a drug reaction
died, one from lactic acidosis. Three HAART cases and 1
no-HAART admission died from conditions not related to
HIV. Two deaths in the HAART group were attributed to
IRIS.
The total cost of hospitalization of all of the admissions,
1657 patient days, was US$257,033. In both groups, non-
curative costs constituted the greatest proportion of total
hospitalization costs (90% HAART; 89% no-HAART).
Within non-curative costs, overheads constituted the larg-
est share of the costs (46% HAART; 47% no-HAART). The
costs of hospitalization of both groups are depicted in
Table 4. Although admission costs were somewhat higher
in the HAART group, the difference was not significant.
Similarly, there were no significant differences in costs
observed between both groups when controlling for
admission to G.F. Jooste alone (p = 0.15) or controlling
for admission to the Carnation step-down ward (p =
Table 1: Demographics and characteristics of HIV-infected patient admissions at G.F. Jooste Hospital.
Variable HAART No-HAART p-value
Number of Admissions
Total admissions 70 60
First admissions 53 53
Median Age 32 (IQR 29-35) 32 (IQR 27-40) p = 0.871
Gender p = 0.647
Men 20 (29%) 15 (25%)
Women 50 (71%) 45 (75%)
Referral source p = 0.000
public primary-care clinic 52 (74%) 29 (48%)
secondary hospital clinic 10 (14%) 2 (3%)
tertiary hospital clinic 3 (4%) 0
private medical doctor 4 (6%) 16 (27%)
not recorded 1 (1%) 13 (22%)
Prior WHO Stage p = 0.040
Stage I 0 (0%) 3 (5%)
Stage II 0 (0%) 0 (0%)
Stage III* 13 (19%) 18 (30%)
Stage IV* 57 (81%) 39 (65%)
CD4 Count × 106 cells/L
Number performed 64 (91%) 11 (18%)
Median CD4 count 57 (IQR 15-115) 16 (IQR 10-316) p = 0.96
Cotrimoxazole prophylaxis 36 7 p = < 0.001
*All forms of tuberculosis were regarded as stage IV as it was not always clear from discharge diagnoses whether tuberculosis was pulmonary or 
extrapulmonaryBMC Infectious Diseases 2009, 9:205 http://www.biomedcentral.com/1471-2334/9/205
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0.76). However, diagnostic and therapeutic costs were
higher in the HAART group.
Discussion
We analysed diagnoses, outcomes and resource utiliza-
tion in 130 secondary hospital HIV admissions compar-
ing patients who recently started HAART with those not
on HAART in a high HIV prevalence area. We found that
the primary reasons for admission were more likely to be
due to adverse drug reactions and less likely to be due to
AIDS events in patients on HAART. IRIS emerged as an
important cause of early morbidity, accounting for 10% of
the primary causes of admission in the HAART group. IRIS
together with adverse drug reactions accounted for a third
of all deaths in patients on HAART.
The patients in our study were severely immune sup-
pressed, as assessed by WHO clinical staging and CD4 cell
counts, which is typical of patients starting HAART in
Africa. We found that tuberculosis was by far the com-
monest diagnosis in both the HAART and no-HAART
admissions. In the West African studies tuberculosis was
the second commonest diagnosis [8,9], but it was the
commonest in another South African study [10], which
reflects the higher TB incidence in South Africa. However,
we found that adverse drug reactions were more com-
monly the primary reason for admission among our
HAART group than the other South African study [10].
Adverse drug reactions were not assessed in the West Afri-
can studies. In a recent study of severe adverse drug reac-
tions in South African medical inpatients, among HIV-
infected patients those on HAART were 10 times more
likely than those not on HAART to be admitted to hospital
with an adverse drug reaction [23], which is in keeping
with our finding that adverse drug reactions were far more
commonly the primary reasons for admission in the
HAART group. IRIS accounted for 10% of our admissions
and was not assessed in either of the West African studies
or the other South African study.
Table 2: Primary Reason for Admission
Disease category HAART
(n = 70) n (%)
No-HAART
(n = 60) n (%)
p-value
AIDS 27* (39%) 38 (63%) p = 0.005
Tuberculosis 17 28
Cryptococcal meningitis 5 3
Cryptosporidiosis 2 0
Pneumocystis pneumonia 1 6
Kaposi sarcoma 1 0
HIV encephalopathy 1 0
Esophageal candidiasis 0 1
Drug reactions 24 (34%) 4 (7%) p < 0.001
Hepatitis 7 3
Stevens-Johnson syndrome 0 1
Anemia (zidovudine) 6
Lactic acidosis (stavudine) 5
Neuropathy (stavudine) 2
Pancreatitis (stavudine or lamivudine) 1
Emesis (nevirapine) 1
Rechallenge HAART 1
Myopathy (zidovudine) 1
HIV-related conditions 7 (10%) 6 (10%) p = 1
Severe bacterial infection 6 4
Chronic diarrhea 1 0
HIV cardiomyopathy 0 2
Other conditions 12 (17%) 12 (20%) p = 0.676
Aseptic meningitis 5 2
TB sequelae 3 0
Deep venous thrombosis 2 4
Drug overdose 1 0
Hematologic disorder 1 1
Renal failure 0 1
Stroke 0 1
Diabetic complications 0 1
Reactive arthritis 0 1
Palliative care 0 1
* Includes 7 admissions for IRIS events (cryptococcal meningitis 3 and tuberculosis 4)BMC Infectious Diseases 2009, 9:205 http://www.biomedcentral.com/1471-2334/9/205
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Hospitalization costs are a major component of costs for
HIV care in developed countries, particularly in patients
with more advanced disease [24]. The hospital sector is
where HIV currently has the greatest impact on the public
health budgets in South Africa, where HIV admissions
account for 25% of all hospital admissions and consume
one eighth of the public-health budget [25]. Costs of
delivering HAART are in part offset by savings on hospital-
ization. A South African study of the cost-effectiveness of
HAART demonstrated dramatic reductions in the costs of
hospitalization and a shift of care delivery to the outpa-
tient setting for patients accessing HAART [26]. We found
that there were significantly more costs for diagnostic and
therapeutic interventions of patients on HAART com-
pared with controls. The higher resource utilization for
diagnostic and therapeutic services in the HAART group
likely reflects the greater complexity of diagnosis in these
patients. The similar median total costs among both arms
of the cohort arise from the fact that the hospitalization
costs are being driven by per diem non-curative costs.
Higher per admission costs for patients on HAART com-
pared with those not on HAART were also reported in
another South African study [27]. In our study, the record-
ing of comorbidities and inclusion of associated diagnos-
tic and therapeutic costs carries forward the work by
Guiness et al in Kenya, which was limited to costs related
to the primary reason for admission [18].
Our findings have several implications. First, starting
HAART at higher baseline CD4 counts would reduce the
incidence of IRIS, many adverse drug reactions, and HIV-
related morbidity. This would result in a shift from inpa-
tient to outpatient HIV care, which would free substantial
resources for the many other competing health care prior-
ities in Africa. Second, the use of safer antiretroviral drugs
(e.g. tenofovir or efavirenz instead of stavudine or nevi-
rapine) will reduce morbidity as adverse drug reactions
were the primary reason for admission in 34% of our
HAART group. The World Health Organization has rec-
ommended this strategy in resource-limited settings, but
Table 3: Length of Stay and Outcome
Variable HAART
(n = 70)
No-HAART
(n = 60)
p-value
Median Length of Stay, days (IQR)
Overall 8.5 (4-16) 8 (5-13) p = 0.63
Medical ward 8 (4-15) 7 (4-10)
Step-down ward 10.5 (4-30.5) 9.5 (5.5-14.5)
Outcome
Total admissions p = 0.139
alive 55 (79%) 53 (88%)
dead 15 (21%) 7 (12%)
First admission p = 0.076
alive 40 (75%) 47 (89%)
dead 13 (25%) 6 (11%)
Discharge (n = 56) (n = 54)
Home 44 (79%) 37 (69%)
Step-down ward 7 (13%) 12 (22%)
Tertiary hospital 4 (7%) 4 (7%)
TB Hospital 1 (2%) 1 (2%)
Table 4: Median Cost in US$ of Hospitalization
Variable HAART No-HAART p-value
Non curative costs G.F. Jooste plus step-down ward* $1199
(IQR $564-2257)
$1128
(IQR $705-1764)
p = 0.595
Diagnostic and therapeutic cost ** $191
(IQR $88-323)
$111
(IQR $62-207)
p = 0.001
Total hospitalization cost per admission $1409
(IQR $724-$2658)
$1304
(IQR $813-2077)
p = 0.525
* Length of stay multiplied by the sum of daily overhead, capital, and clinical staff costs.
** Sum of laboratory investigations, radiology, intravenous fluids and blood, and non-ART medicationsBMC Infectious Diseases 2009, 9:205 http://www.biomedcentral.com/1471-2334/9/205
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recognizes that agents with better safety profiles are cur-
rently more costly [28]. Third, the large burden of tuber-
culosis we found, which is typical of other African studies,
emphasises that prevention, diagnosis and treatment of
tuberculosis should be integrated into antiretroviral pro-
grammes. Fourth, differential diagnosis and management
in patients presenting with early morbidity on HAART is
complex and difficult in resource-limited settings with
limited diagnostic facilities. The differentiation of IRIS
from new opportunistic disease or drug toxicity is particu-
larly complex. Training manuals for health care workers in
Africa should include the causes of early morbidity on
HAART, as well as the importance of their early recogni-
tion and appropriate management.
Our study has a number of limitations. We collected data
retrospectively, which is always less reliable and complete
than in prospective studies. We could only detect large dif-
ference between patients in the HAART and no-HAART
groups given our relatively small sample size and compar-
isons between the two groups should be interpreted with
caution. Our study was also only limited to inpatients and
should not be extrapolated to outpatients. However,
detailed costing was done on all 130 admissions, which
involved a considerable amount of data collection. Limi-
tations of our cost analysis include lack of a detailed
assessment of clinical staffing costs, and exclusion of the
indirect and direct non-health care costs borne by patients
and their families. Importantly, future cost savings from
HAART, notably reduction in rates of hospitalisation,
were not assessed. Our study was conducted early on in
the roll out of antiretroviral therapy when the numbers of
patients on HAART in our catchment area was considera-
bly lower than it is currently, but CD4 counts at HAART
initiation were lower than they are currently, which
should result in lower hospitalization rates and possibly
different reasons for hospitalisation. CD4 counts were dis-
couraged on inpatients as a cost-saving measure, but were
done as outpatients. Because only a minority of patients
in the no-HAART group was in HIV care while all those on
HAART were, we had access to CD4 counts in most of the
HAART group and few of the no-HAART group. Finally,
although access to diagnostic and therapeutic interven-
tions was similar for both groups, we could not exclude
the possibility that clinicians looking after patients on
HAART might have been more active in investigating and
treating them due to a perceived better prognosis.
Conclusion
In conclusion, our study provides disease and economic
information that may assist with the planning and deliv-
ery of comprehensive HIV/AIDS care in Africa. A high pro-
portion of admissions for patients on HAART is due to
adverse drug reactions or IRIS. Further large prospective
cohort studies should be conducted to identify the nature
of the early morbidity on HAART in Africa more accu-
rately, and to identify strategies to prevent, diagnose and
manage these morbidities.
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